Hematological indicators

PreclinicalBiologic

Hematological indicators is one of 56 biologic programs targeting Cardiovascular Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

146 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

2 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

6 3

Dobutrex

Lexiscan

Thalitone

Bumex

VValidus Pharmaceuticals

Approved

—7

Atacand

IIstituto Clinico Humanitas

Colcrys

1 9

Pelacarsen

Novartis

Phase 3

1 10

Cagrilintide

Novo Nordisk

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiovascular Disease1 trial

Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases

Enrolling by invitation·YYa-Wei Xu··NCT06690684·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hematological indicators. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hematological indicators compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hematological indicators. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ya-Wei Xu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: YYa-Wei Xu

Hematological indicators

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News